Therefore, to explore the cost-effectiveness of first-line single-agent atezolizumab chemotherapy for patients with PD-L1 high-expressing EGFR and ALK wild-type advanced NSCLC, we performed an economic study based on the updated IMpower110 from the perspective of the Chinese healthcare system using the Partitioned Survival model (PartSA model) and Dynamic Markov model (Markov model) were constructed. Here, ALK is linked to non-small cell lung carcinoma.